Trial · NCT02957682
Adverse events556
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 556
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Placebo | 65 | 1,084 | 72 |
| other | Bronchitis | Infections and infestations | Alirocumab 75 Q2W/Up150 Q2W | 60 | 1,087 | 78 |
| other | Influenza | Infections and infestations | Placebo | 69 | 1,084 | 77 |
| other | Influenza | Infections and infestations | Alirocumab 75 Q2W/Up150 Q2W | 63 | 1,087 | 69 |
| other | Nasopharyngitis | Infections and infestations | Placebo | 89 | 1,084 | 117 |
| other | Nasopharyngitis | Infections and infestations | Alirocumab 75 Q2W/Up150 Q2W | 82 | 1,087 | 98 |
| other | Urinary tract infection | Infections and infestations | Placebo | 46 | 1,084 | 65 |
| other | Urinary tract infection | Infections and infestations | Alirocumab 75 Q2W/Up150 Q2W | 61 | 1,087 | 78 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Placebo | 71 | 1,084 | 82 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Alirocumab 75 Q2W/Up150 Q2W | 60 | 1,087 | 66 |
| other | Headache | Nervous system disorders | Placebo | 85 | 1,084 | 123 |
| other | Headache | Nervous system disorders | Alirocumab 75 Q2W/Up150 Q2W | 71 | 1,087 | 83 |
| other | Hypertension | Vascular disorders | Placebo | 73 | 1,084 | 93 |
| other | Hypertension | Vascular disorders | Alirocumab 75 Q2W/Up150 Q2W | 64 | 1,087 | 81 |
| serious | Angina unstable | Cardiac disorders | Placebo | 16 | 1,084 | 17 |
| serious | Angina unstable | Cardiac disorders | Alirocumab 75 Q2W/Up150 Q2W | 14 | 1,087 | 17 |
| serious | Atrial fibrillation | Cardiac disorders | Placebo | 13 | 1,084 | 16 |
| serious | Atrial fibrillation | Cardiac disorders | Alirocumab 75 Q2W/Up150 Q2W | 5 | 1,087 | 5 |
| serious | Angina pectoris | Cardiac disorders | Placebo | 10 | 1,084 | 12 |
| serious | Angina pectoris | Cardiac disorders | Alirocumab 75 Q2W/Up150 Q2W | 11 | 1,087 | 11 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02957682/events